Cannabis in cancer: helpful for symptoms, but could it interfere with immunotherapy?

Cannabis is useful for cancer-related pain and nausea, and preclinical data suggest anti-tumor properties, but its immunomodulatory effects could potentially interfere with cancer immunotherapy and bone marrow transplants.

Almogi-Hazan, Osnat et al.·Rambam Maimonides medical journal·2020·Moderate EvidenceReview
RTHC-02379ReviewModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Current cancer applications of cannabinoids are mainly palliative (pain and anti-emetic effects). Preclinical data on anti-proliferative properties remain inconsistent, with no conclusive animal model or clinical trial data. Critically, the immunomodulatory effects of cannabinoids may conflict with cancer immunotherapy and bone marrow transplant approaches, where robust immune function is essential.

Key Numbers

No specific clinical outcome data. Review synthesized preclinical and clinical knowledge about cannabinoid immunomodulation in oncology.

How They Did This

Review covering preclinical models, limited clinical data, and the specific concern about interactions between cannabinoid immunomodulation and cancer immunotherapy.

Why This Research Matters

As immunotherapy becomes a standard cancer treatment, the potential for cannabis to dampen the immune response it relies on is a clinically important but understudied concern.

The Bigger Picture

The potential contradiction between cannabis's anti-tumor properties and its immune-dampening effects highlights the complexity of using cannabinoids alongside modern cancer treatments.

What This Study Doesn't Tell Us

Narrative review. Anti-tumor data are preclinical and inconsistent. Immunomodulatory interactions with immunotherapy are theoretical. No clinical trials address this interaction.

Questions This Raises

  • ?Should cancer patients on immunotherapy avoid cannabis?
  • ?Could timed or targeted cannabinoid dosing avoid immune interference?

Trust & Context

Key Stat:
Potential conflict between cannabis and cancer immunotherapy
Evidence Grade:
Thoughtful review raising an important clinical question, but based on indirect evidence and theoretical concerns.
Study Age:
2020 review.
Original Title:
The Highs and Lows of Cannabis in Cancer Treatment and Bone Marrow Transplantation.
Published In:
Rambam Maimonides medical journal, 11(1) (2020)
Database ID:
RTHC-02379

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Should cancer patients use cannabis during immunotherapy?

This review raises concern that cannabis's immunomodulatory effects could potentially interfere with cancer immunotherapy, which relies on a strong immune response. The interaction has not been studied in clinical trials.

Can cannabis fight cancer directly?

Preclinical data show some anti-proliferative effects, but results are inconsistent and no clinical trials have confirmed direct anti-tumor benefits in patients.

Read More on RethinkTHC

Cite This Study

RTHC-02379·https://rethinkthc.com/research/RTHC-02379

APA

Almogi-Hazan, Osnat; Khuja, Iman; Ritter, Sivan; Or, Reuven. (2020). The Highs and Lows of Cannabis in Cancer Treatment and Bone Marrow Transplantation.. Rambam Maimonides medical journal, 11(1). https://doi.org/10.5041/RMMJ.10391

MLA

Almogi-Hazan, Osnat, et al. "The Highs and Lows of Cannabis in Cancer Treatment and Bone Marrow Transplantation.." Rambam Maimonides medical journal, 2020. https://doi.org/10.5041/RMMJ.10391

RethinkTHC

RethinkTHC Research Database. "The Highs and Lows of Cannabis in Cancer Treatment and Bone ..." RTHC-02379. Retrieved from https://rethinkthc.com/research/almogi-hazan-2020-the-highs-and-lows

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.